From: Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV1
Trial | Age | Sex | Race | Never smoked | Duration of asthma | FEV1 at baseline | PEFd at baseline |
---|---|---|---|---|---|---|---|
(Treated patients) | Mean ± SD [years] | Male, n (%); Female, n (%) | White, n (%); Asian, n (%); Black a , n (%); American Indian b , n (%); Hawaiian c , n (%) | n (%) | Mean ± SD [years] | Mean ± SD [L]/[% pred.] | Weekly mean ± SD [mL/min] |
Adolescents (12 to 17 years) | |||||||
RubaTinA-asthma® (N = 397) | 14.3 ± 1.7 | 258 (65.0); 139 (35.0) | 368 (92.7); 13 (3.3); 14 (3.5); 2 (0.5); 0 | 396 (99.7) | 7.9 ± 4.1 | 2.75 ± 0.66/82.8 ± 10.6 | 360.0 ± 91.1 |
PensieTinA-asthma® (N = 392) | 14.2 ± 1.7 | 242 (61.7); 150 (38.3) | 371 (94.6); 10 (2.6); 8 (2.0); 3 (0.8); 0 | 392 (100) | 7.8 ± 3.9 | 2.53 ± 0.62/79.5 ± 11.5 | 346.1 ± 91.8 |
Adults (18 to 75 years) | |||||||
GraziaTinA-asthma® (N = 464) | 42.9 ± 13.0 | 183 (39.4); 281 (60.6) | 362 (78.0); 85 (18.3); 1 (0.2); 16 (3.4); 0 | 382 (82.3) | 16.2 ± 11.9 | 2.42 ± 0.71/77.7 ± 11.9 | 369.8 ± 114.9 |
MezzoTinA-asthma® (N = 2100) | 43.1 ± 12.9 | 861 (41.0); 1239 (59.0) | 1005 (47.9); 893 (42.5); 81 (3.9); 118 (5.6); 3 (0.1) | 1756 (83.6) | 21.8 ± 14.3 | 2.27 ± 0.65/75.1 ± 11.5 | 349.6 ± 117.2 |
CadenTinA-asthma® (N = 285) | 44.5 ± 12.7 | 109 (38.2); 176 (61.8) | 0; 285 (100.0); 0; 0; 0 | 214 (75.1) | 22.4 ± 14.2 | 2.28 ± 0.65/80.2 ± 12.5 | 375.5 ± 118.4 |
PrimoTinA-asthma® (N = 912) | 53.0 ± 12.4 | 361 (39.6); 551 (60.4) | 759 (83.2); 103 (11.3); 47 (5.2); 1 (0.1); 2 (0.2) | 692 (75.9) | 30.3 ± 13.9 | 1.60 ± 0.54/56.0 ± 13.1 | 270.7 ± 111.1 |